Resource utilization in cancer patients with bisphosphonate-associated osteonecrosis of the jaw

Oral Diseases

Volumn 20, Issue 1, 2014, Pages 94-99

  Najm, Ms ^a   Solomon, Dh ^b   Woo, S B ^b,c   Treister, Ns ^b,c  

^a MUSTANSIRIYAH UNIVERSITY   (Iraq)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

Bisphosphonates; BONJ; Cancer; Cost; Osteonecrosis

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE NECROSIS; BREAST CANCER; CANCER PATIENT; CANCER THERAPY; CLINICAL PRACTICE; CONSULTATION; DYSESTHESIA; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HEALTH CARE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; IMAGING; JAW OSTEONECROSIS; LABORATORY TEST; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NEURALGIA; PRIORITY JOURNAL; PROCEDURES; PROSTATE CANCER; SECONDARY INFECTION; STOMATOLOGY; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; ECONOMICS; HEALTH CARE PLANNING; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDY; UTILIZATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 84890119859     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/odi.12080     Document Type: Article

References (22)

1. https://ocm.ama-assn.org, CodeManager (Metropolitan Boston).
2. (2008). The Red Book of Medicines, Thomson Health Care: Newark.
3. Alons K, Kuijpers SC, deJong E, vanMerkesteyn JP (2009). Treating low- and medium-potency bisphosphonate-related osteonecrosis of the jaws with a protocol for the treatment of chronic suppurative osteomyelitis: report of 7 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 107: e1-e7.
4. Bagan JV, Jimenez Y, Murillo J et al (2006). Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases. Oral Oncol 42: 327-329.
5. Bamias A, Kastritis E, Bamia C et al (2005). Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23: 8580-8587.
6. Chiandussi S, Biasotto M, Dore F, Cavalli F, Cova MA, Di Lenarda R (2006). Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws. Dentomaxillofac Radiol 35: 236-243.
7. Edwards BJ, Hellstein JW, Jacobsen PL, Kaltman S, Mariotti A, Migliorati CA (2008). Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 139: 1674-1677.
8. Khan AA, Sandor GK, Dore E et al (2008). Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 35: 1391-1397.
9. Lam DK, Sandor GK, Holmes HI, Evans AW, Clokie CM (2007). A review of bisphosphonate-associated osteonecrosis of the jaws and its management. J Can Dent Assoc 73: 417-422.
10. Lo JC, O'Ryan FS, Gordon NP et al (2009). Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 68: 243-253.
11. Marx RE, Sawatari Y, Fortin M, Broumand V (2005). Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63: 1567-1575.
12. Migliorati CA, Siegel MA, Elting LS (2006). Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 7: 508-514.
13. Miksad RA, Lai KC, Dodson TB et al (2011). Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw. Oncologist 16: 121-132.
14. Ruggiero SL, Woo SB (2008). Bisphosphonate-related osteonecrosis of the jaws. Dent Clin North Am 52: 111-128.
15. Ruggiero S, Gralow J, Marx RE et al (2006). Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2: 7-14.
16. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B (2009). American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg 67: 2-12.
17. Thumbigere-Math V, Sabino MC, Gopalakrishnan R et al (2009). Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients. J Oral Maxillofac Surg 67: 1904-1913.
18. Treister N, Sheehy N, Bae EH, Friedland B, Lerman M, Woo S (2009). Dental panoramic radiographic evaluation in bisphosphonate-associated osteonecrosis of the jaws. Oral Dis 15: 88-92.
19. Tubiana-Hulin M, Spielmann M, Roux C et al (2009). Physiopathology and management of osteonecrosis of the jaws related to bisphosphonate therapy for malignant bone lesions. A French expert panel analysis. Crit Rev Oncol Hematol 71: 12-21.
20. Weitzman R, Sauter N, Eriksen EF et al (2007). Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients-May 2006. Crit Rev Oncol Hematol 62: 148-152.
21. Williamson RA (2010). Surgical management of bisphosphonate induced osteonecrosis of the jaws. Int J Oral Maxillofac Surg 39: 251-255.
22. Wongchuensoontorn C, Liebehenschel N, Wagner K et al (2009). Pathological fractures in patients caused by bisphosphonate-related osteonecrosis of the jaws: report of 3 cases. J Oral Maxillofac Surg 67: 1311-1316.